SEVERE WX : Flood Watch - Flash Flood Watch - Flood Advisory View Alerts

Scientists make 'exciting' advancement in certain breast cancer drugs

Two new drugs for advanced HER2-positive breast cancer were tested in separate studies, and scientists say they've made progress in the development of new tr...

Posted: Dec 17, 2019 8:29 AM

Two new drugs for advanced HER2-positive breast cancer were tested in separate studies, and scientists say they've made progress in the development of new treatment options.

This type of breast cancer tests positive for higher levels of a protein called HER2.

One study, published in the New England Journal of Medicine last week, found that adding the experimental drug tucatinib to a chemotherapy regimen consisting of the drugs trastuzumab and capecitabine could improve survival for adults with advanced HER2-positive metastatic breast cancer.

The other study, also published in the New England Journal of Medicine last week, found that the experimental drug conjugate called trastuzumab deruxtecan was able to substantially reduce tumor activity in patients with HER2-positive metastatic breast cancer.

"Both studies are evaluating new drugs for HER2-positive breast cancer, which represents about 15% to 20% of all breast cancers," said Dr. Eric Winer, chief of the division of breast oncology at Dana-Farber Cancer Institute in Boston and professor of medicine at Harvard Medical School, who was the senior author of the tucatinib study.

"What's so exciting is we have developed multiple new drugs for HER2-positive breast cancer -- we have new drugs for all subtypes of breast cancer -- but the changes are most dramatic in the setting of HER2-positive breast cancer," Winer said.

"It is the single area in breast cancer where we have made the most dramatic progress and continue to," he said. "For individuals with advanced breast cancer we can individualize therapy more than in the past; it is no longer one size fits all."

The tucatinib study: 'It was pretty well tolerated'

The tucatinib study included 613 patients who previously underwent chemotherapy for HER2-positive metastatic breast cancer by taking the drugs trastuzumab, pertuzumab and trastuzumab emtansine -- but that treatment approach had stopped working for the patients.

For the study, the patients were randomly assigned to either the drug tucatinib or a placebo and received chemotherapy with the drugs trastuzumab and capecitabine.

The researchers found that in the first year of treatment, 33.1% of patients in the tucatinib group did not see their cancer progress compared with 12.3% of patients in the placebo group.

The researchers also found that overall survival two years after starting treatment was 44.9% among patients in the tucatinib group and 26.6% among those in the placebo group.

Side effects of the tucatinib treatment that emerged in the study included the risks of diarrhea and elevated levels of an enzyme in the body called aminotransferase.

"But in general it was pretty well tolerated," Winer said.

Next year, the biotechnology company Seattle Genetics, which develops tucatinib, plans to submit a new drug application to the US Food and Drug Administration and an application to the European Medicines Agency with the goal of bringing this new medicine to the public, Dr. Roger Dansey, chief medical officer at the company, said in a press release on Wednesday.

"Continued innovation to bring new therapies for the treatment of metastatic HER2-positive breast cancer is urgently needed, and we are encouraged by the impressive clinical activity demonstrated with the addition of tucatinib to trastuzumab and capecitabine," he said in part.

The trastuzumab deruxtecan study: 'I am cautiously optimistic'

The trastuzumab deruxtecan study included 184 patients who had already undergone multiple prior treatments for HER2-positive breast cancer. The patients were given the recommended dose of trastuzumab deruxtecan at 5.4 mg per kilogram of body weight.

The researchers found that the patients saw no further progression of their cancer for a median of 16.4 months and that the cancer in 60.9% of the patients shrunk by at least 50% in response to the treatment. However, the treatment came with some side effects, including nausea, myelosuppression -- the decline of bone marrow activity -- and interstitial lung disease.

Overall, "it is rare that a drug has effects on women heavily pretreated," said Dr. Otis Brawley, Bloomberg Distinguished Professor of oncology and epidemiology at Johns Hopkins University, who was not involved in the new study.

"I am cautiously optimistic," he said, but added that more research is needed to determine whether trastuzumab deruxtecan could help patients live longer.

Dr. Ian Krop, a principal investigator of the study and associate chief of the division of breast oncology at Dana-Farber Cancer Institute in Boston, called the research results "striking" in a press release on Wednesday.

"These results are particularly striking as trastuzumab deruxtecan prompted a high level of durable tumor reduction among patients, the majority of whom had exhausted most if not all standard therapies for HER2-metastatic breast cancer," he said. "We are excited by these results and their potential to help patients with this advanced stage of breast cancer."

Huntsville
Overcast
64° wxIcon
Hi: 67° Lo: 63°
Feels Like: 64°
Florence
Overcast
67° wxIcon
Hi: 67° Lo: 64°
Feels Like: 67°
Fayetteville
Scattered Clouds
64° wxIcon
Hi: 66° Lo: 63°
Feels Like: 64°
Decatur
Overcast
64° wxIcon
Hi: 67° Lo: 63°
Feels Like: 64°
Scottsboro
Broken Clouds
64° wxIcon
Hi: 66° Lo: 63°
Feels Like: 64°
WAAY Radar
WAAY WAAY-TV Cam
WAAY Temperatures

Alabama Coronavirus Cases

Confirmed Cases: 133433

Reported Deaths: 2349
CountyConfirmedDeaths
Jefferson19306349
Mobile13233291
Montgomery8748177
Madison770978
Tuscaloosa7418116
Lee579261
Shelby578750
Baldwin514149
Marshall389244
Etowah340247
Calhoun340140
Morgan323926
Houston276423
Elmore259647
DeKalb237519
St. Clair226337
Walker225383
Talladega210628
Limestone203319
Cullman186818
Dallas175926
Franklin175229
Russell17322
Autauga171525
Lauderdale167333
Colbert162926
Blount158015
Escambia157725
Jackson154011
Chilton152431
Dale134644
Covington133427
Coffee12988
Pike11799
Chambers114442
Tallapoosa113885
Clarke107017
Marion95429
Butler91139
Barbour8517
Winston71812
Marengo70519
Lowndes65227
Pickens64514
Bibb63810
Randolph62713
Hale61928
Lawrence60522
Bullock59714
Geneva5864
Cherokee58315
Monroe5808
Clay5547
Washington55113
Perry5396
Conecuh53011
Wilcox53011
Crenshaw52732
Henry4835
Macon47920
Fayette4358
Sumter43219
Lamar3572
Choctaw34412
Cleburne3356
Greene30315
Coosa1673
Out of AL00
Unassigned00

Tennessee Coronavirus Cases

Confirmed Cases: 186798

Reported Deaths: 2277
CountyConfirmedDeaths
Shelby30397449
Davidson26194297
Hamilton926392
Knox911575
Rutherford911388
Williamson513936
Sumner475093
Wilson341243
Putnam317038
Montgomery301543
Out of TN296825
Unassigned29046
Bradley288317
Madison278060
Sevier255315
Blount246123
Maury228923
Washington223234
Robertson218835
Sullivan209332
Hamblen187325
Tipton176617
Trousdale16517
Gibson158620
Hardeman154625
Wayne14896
Bedford131717
Dyer131413
Dickson123014
Cumberland116918
Fayette116718
Coffee115612
Anderson115311
Henderson115121
Weakley114519
Carter114128
Loudon11316
Greene111839
Obion11129
McMinn109424
Jefferson108514
Macon103320
Warren10197
Monroe101017
Lawrence100311
Hardin99115
Lauderdale94915
Franklin9458
Haywood93316
Lake9192
Roane8643
Carroll84918
Bledsoe8484
McNairy82418
White8069
Cheatham80510
Rhea79111
Hawkins78016
Cocke7379
Marshall7335
Overton7085
Smith69710
Johnson6622
Henry6129
Chester60510
Lincoln5961
Giles57617
Hickman5535
DeKalb55013
Crockett52919
Marion5167
Decatur4956
Fentress4623
Claiborne4384
Campbell4243
Polk38010
Grainger3603
Union3451
Benton3349
Jackson3145
Morgan3103
Cannon2810
Unicoi2811
Grundy2635
Humphreys2433
Sequatchie2262
Meigs2213
Clay2155
Scott2082
Houston1981
Stewart1822
Lewis1791
Moore1611
Van Buren1590
Perry1490
Hancock1073
Pickett1072

Community Events